Bronchial hyperresponsiveness (BHR) to inhaled histamine has often been cited as the gold standard in asthma diagnosis, but recently this has been questioned. This report assesses the relationship of BHR to asthma symptoms and asthma diagnosis in a large community-based sample of children. A total of 2,053 children 7 to 10 yr of age were randomly sampled from Auckland primary schools and assessed by a questionnaire and histamine inhalation challenge. In all, 14.3% had had asthma diagnosed, 29.6% reported having had one of the four respiratory symptoms in in the previous 12 months, and 15.9% had BHR (PD20 less than or equal to 7.8 mumol histamine). After a cumulative dose of 3.9 mumol histamine, the percent change in FEV1 from postsaline FEV1 was unimodally distributed, with those in whom asthma had been diagnosed dominating the severe end of the spectrum. However, 53% of those with BHR had no asthma diagnosis, and 41% had no current asthma symptoms. On the other hand, 48% of all subjects with diagnosed asthma and 42% of children with diagnosed asthma and current symptoms did not have BHR. Although severity of BHR tended to increase with wheezing frequency, all grades of severity (including no BHR) were found for any given frequency of wheeze. An existing diagnosis of asthma identified symptomatic children more accurately than did BHR, regardless of the criteria used for BHR or for "symptomatic" and irrespective of ethnic group. In conclusion, BHR is related to, but not identical to, clinical asthma. Bronchial challenge testing is an important tool of respiratory research, but cannot reliably or precisely separate asthmatics from nonasthmatics in the general community.

This study examines the relationship between socioeconomic status (SES) and asthma prevalence and the use of asthma medication. One thousand and fifty European children aged eight and nine years were studied by parent completed questionnaire and histamine inhalation challenge. After controlling for sex of the child and for smokers in the house there were significantly higher lifetime (P = 0.029) and current (P = 0.046) prevalence rates of wheeze in children in low SES groups. There was no relationship between SES and asthma diagnosis, bronchial hyperresponsiveness (BHR: PD20 less than 7.8 mumol), or any combination of BHR with symptoms or diagnosis. The use of bronchodilators and asthma prophylactic drugs was less frequent in the low SES groups of children with wheeze in the last 12 months both with concurrent BHR or irrespective of BHR than in those in high SES groups.

No abstract

No abstract